Rheumatoid arthritis On May 15, 2013, both companies announced that 2 new trials were starting (COMPARE and ASCERTAIN) and the first patients had already been enrolled. In June 2015, a phase III trial (with methotrexate) for RA reported meeting its three coprimary endpoints. In November 2015, the SARIL-RA-TARGET trial reported good results (meeting both its coprimary end points). In November 2016, the MONARCH phase III trial comparing<unk>  to adalimumab (an anti-TNF) found<unk>  superior at reducing the DAS28-ESR score in patients with RA after 24 weeks. In July 2019, a multi-center trial was launched to study<unk>  in Patients With Glucocorticoid-Dependent Sarcoidosis.'
Sarilumab
Emapalumab
Burosumab
Olaratumab
Dupilumab
Evolocumab
Anifrolumab
Alirocumab